Concurrent neoadjuvant chemotherapy and estrogen deprivation in patients with estrogen receptor‐positive, human epidermal growth factor receptor 2‐negative breast cancer (CBCSG‐036): A randomized, controlled, multicenter trial-Reference-Cited by-同舟云学术

Concurrent neoadjuvant chemotherapy and estrogen deprivation in patients with estrogen receptor‐positive, human epidermal growth factor receptor 2‐negative breast cancer (CBCSG‐036): A randomized, controlled, multicenter trial

Published:2019-03-20 Issue: Volume: Page:
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Yu Ke‐Da¹²^ORCID,Wu Si‐Yu¹²,Liu Guang‐Yu¹²,Wu Jiong¹²,Di Gen‐Hong¹²,Hu Zhen¹²,Hou Yi‐Feng¹²,Chen Can‐Ming¹²,Fan Lei¹²,Tang Li‐Chen¹²,Shen Zhen‐Zhou¹²,Wu Ke‐Jin³,Zhuang Zhi‐Gang⁴,Zhang Hong‐Wei⁵,Shao Zhi‐Ming¹²

Affiliation:

1. Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai Fudan University Shanghai Cancer Center Shanghai China

2. Department of Oncology Shanghai Medical College, Fudan University Shanghai China

3. Department of Breast Surgery Obstetrics and Gynecology Hospital of Fudan University Shanghai China

4. Department of Breast Surgery the First Maternity and Infant Health Hospital, Tongji University Shanghai China

5. Department of General Surgery Zhongshan Hospital, Fudan University Shanghai China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.32057

Reference33 articles.

1. De‐escalating and escalating treatments for early‐stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017;Curigliano G;Ann Oncol,2017

2. Pathological complete response and long‐term clinical benefit in breast cancer: the CTNeoBC pooled analysis;Cortazar P;Lancet,2014

3. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor‐positive breast cancer;Semiglazov VF;Cancer,2007

4. Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006‐03, a multicenter, randomized, phase‐II study;Alba E;Ann Oncol,2012

5. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double‐blind randomized trial;Smith IE;J Clin Oncol,2005

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neoadjuvant Chemotherapy with Concurrent Letrozole for Estrogen Receptor-Positive and HER2-Negative Breast Cancer: An Open-Label, Single-Center, Nonrandomized Phase II Study (NeoCHAI);Cancers;2024-09-10

2. Combination of chemotherapy and endocrine treatment in breast cancer — is it still a taboo?;Oncology in Clinical Practice;2024-08-21

3. Chemotherapy combined with endocrine therapy: Old wine in a new bottle?;Clinical Breast Cancer;2024-08

4. Efficacy and safety of neoadjuvant therapy for HR-positive/HER2-negative early breast cancer: a Bayesian network meta-analysis;Expert Review of Anticancer Therapy;2024-05-17

5. Exploring the effectiveness of molecular subtypes, biomarkers, and genetic variations as first-line treatment predictors in Asian breast cancer patients: a systematic review and meta-analysis;Systematic Reviews;2024-04-04